Have a personal or library account? Click to login
Target Achievements of Low-Density Lipoprotein Cholesterol, Blood Pressure, and Glucose in Patients with Diabetes after Acute Coronary Syndrome: Findings from the Chinese Cardiovascular Association Database – iHeart Project Cover

Target Achievements of Low-Density Lipoprotein Cholesterol, Blood Pressure, and Glucose in Patients with Diabetes after Acute Coronary Syndrome: Findings from the Chinese Cardiovascular Association Database – iHeart Project

Global Heart
Volume 20 (2025): Issue 1
By: Jing Yang,  Rui Zhang,  Bing Han,  Hui Li,  Jingfeng Wang,  Yihui Xiao,  Xiaofan Yu,  Shaofeng Guan,  Cuilian Dai,  Hua Yan,  Tingbo Jiang,  Hanbin Cui,  Shuang Yang,  Zeqi Zheng,  Yugang Dong,  Annai Wang,  Guohai Su and  Yan Wang  
Open Access
|Feb 2025

References

  1. 1Timmis A, Kazakiewicz D, Townsend N, Huculeci R, Aboyans V, Vardas P. Global epidemiology of acute coronary syndromes. Nat Rev Cardiol. 2023; 20(11):778–788. DOI: 10.1038/s41569-023-00884-0
    Back to article
  2. 2Mensah GA, Fuster V, Murray CJL, Roth GA. Global Burden of Cardiovascular Diseases and Risks Collaborators. Global Burden of Cardiovascular Diseases and Risks, 1990–2022. J Am Coll Cardiol. 2023 Dec 19; 82(25):2350–2473. DOI: 10.1016/j.jacc.2023.11.007
    Back to article
  3. 3Godoy LC, Rao V, Farkouh ME. Coronary revascularization of patients with diabetes mellitus in the setting of acute coronary syndromes. Circulation. 2019; 140(15):1233–1235. DOI: 10.1161/CIRCULATIONAHA.119.040683
    Back to article
  4. 4Giraldez RR, Clare RM, Lopes RD, Dalby AJ, Prabhakaran D, Brogan GX Jr, et al. Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome. Am Heart J. 2013; 165(6):918–925.e2. DOI: 10.1016/j.ahj.2013.01.005
    Back to article
  5. 5Yandrapalli S, Nabors C, Goyal A, Aronow WS, Frishman WH. Modifiable risk factors in young adults with first myocardial infarction. J Am Coll Cardiol. 2019; 73(5):573–584. DOI: 10.1016/j.jacc.2018.10.084
    Back to article
  6. 6Zhou M, Liu J, Hao Y, Liu J, Huo Y, Smith SC Jr, et al. Prevalence and in-hospital outcomes of diabetes among patients with acute coronary syndrome in China: Findings from the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome Project. Cardiovasc Diabetol. 2018; 17(1):147. DOI: 10.1186/s12933-018-0793-x
    Back to article
  7. 7Mahendran DC, Hamilton G, Weiss J, Churilov L, Lew J, Khoo K, et al. Prevalence of pre-existing dysglycaemia among inpatients with acute coronary syndrome and associations with outcomes. Diabetes Res Clin Pract. 2019; 154:130–137. DOI: 10.1016/j.diabres.2019.07.002
    Back to article
  8. 8Ostadal P, Steg PG, Poulouin Y, Bhatt DL, Bittner VA, Chua T, et al. Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: A post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2022; 10(5):330–340. DOI: 10.1016/S2213-8587(22)00043-2
    Back to article
  9. 9Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023; 44(38):3720–3826. DOI: 10.1093/eurheartj/ehad191
    Back to article
  10. 10Xi C, Bo F, Junbo G, Lixin G, Yong H, et al. Chinese expert consensus on the risk assessment and management of panvascular disease inpatients with type 2 diabetes mellitus (2022 edition). Cardiology Plus. 2022; 7(4):162–177, DOI: 10.1097/CP9.0000000000000029
    Back to article
  11. 11Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023; 44(39):4043–4140. DOI: 10.1093/eurheartj/ehad192. Erratum in: Eur Heart J. 2023; 44(48):5060. Erratum in: Eur Heart J. 2024 Feb 16; 45(7):518.
    Back to article
  12. 12Bohn B, Schofl C, Zimmer V, Hummel M, Heise N, Siegel E, et al. Achievement of treatment goals for secondary prevention of myocardial infarction or stroke in 29,325 patients with type 2 diabetes: A German/Austrian DPV-multicenter analysis. Cardiovasc Diabetol. 2016; 15:72. DOI: 10.1186/s12933-016-0391-8
    Back to article
  13. 13Reibis R, Treszl A, Bestehorn K, Karoff M, Schwaab B, Wirth A, et al. Comparable short-term prognosis in diabetic and non-diabetic patients with acute coronary syndrome after cardiac rehabilitation. Eur J Prev Cardiol. 2012; 19(1):15–22. DOI: 10.1177/1741826710393993
    Back to article
  14. 14Kim H, Jung DY, Lee SH, Cho JH, Yim HW, Kim HS. Long-term changes in HbA1c according to blood glucose control status during the first 3 months after visiting a tertiary university hospital. J Korean Med Sci. 2022; 37(38):e281. DOI: 10.3346/jkms.2022.37.e281
    Back to article
  15. 15Landmesser U, McGinniss J, Steg PG, Bhatt DL, Bittner VA, Diaz R, et al. Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab. Eur J Prev Cardiol. 2022; 29(14):1842–1851. DOI: 10.1093/eurjpc/zwac107
    Back to article
  16. 16Hopstock LA, Morseth B, Cook S, Eggen AE, Grimsgaard S, Lundblad MW, et al. Treatment target achievement after myocardial infarction and ischaemic stroke: cardiovascular risk factors, medication use, and lifestyle: The Tromsø Study 2015–16. Eur J Prev Cardiol. 2022; 29(2):362–370. DOI: 10.1093/eurjpc/zwab050
    Back to article
  17. 17Wright AK, Suarez-Ortegon MF, Read SH, Kontopantelis E, Buchan I, Emsley R, et al. Risk factor control and cardiovascular event risk in people with type 2 diabetes in primary and secondary prevention settings. Circulation. 2020; 142(20):1925–1936. DOI: 10.1161/CIRCULATIONAHA.120.046783
    Back to article
  18. 18Sud M, Han L, Koh M, Abdel-Qadir H, Austin PC, Farkouh ME, et al. Low-density lipoprotein cholesterol and adverse cardiovascular events after percutaneous coronary intervention. J Am Coll Cardiol. 2020; 76(12):1440–1450. DOI: 10.1016/j.jacc.2020.07.033
    Back to article
  19. 19Rawshani A, Rawshani A, Franzén S, Sattar N, Eliasson B, Svensson AM, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018; 379(7):633–644. DOI: 10.1056/NEJMoa1800256
    Back to article
  20. 20Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbæk A, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): A cluster-randomised trial. Lancet. 2011; 378(9786):156–67. DOI: 10.1016/S0140-6736(11)60698-3
    Back to article
  21. 21Ueki K, Sasako T, Okazaki Y, Kato M, Okahata S, Katsuyama H, et al. J-DOIT3 Study Group. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): An open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2017; 5(12):951–964. DOI: 10.1016/S2213-8587(17)30327-3
    Back to article
  22. 22Griffin SJ, Rutten GEHM, Khunti K, Witte DR, Lauritzen T, Sharp SJ, et al. Long-term effects of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial. Lancet Diabetes Endocrinol. 2019; 7(12):925–937. DOI: 10.1016/S2213-8587(19)30349-3
    Back to article
  23. 23Ferrari, R, Ford I, Greenlaw N, Tardif JC, Tendera M, Abergel H, et al. Geographical variations in the prevalence and management of cardiovascular risk factors in outpatients with CAD: Data from the contemporary CLARIFY registry. Eur J Prev Cardiol. 2015; 22(8):1056–65. DOI: 10.1177/2047487314547652
    Back to article
  24. 24Gaba P, O’Donoghue ML, Park JG, Wiviott SD, Atar D, Kuder JF, et al. Association between achieved low-density lipoprotein cholesterol levels and long-term cardiovascular and safety outcomes: An Analysis of FOURIER-OLE. Circulation. 2023; 147(16):1192–1203. DOI: 10.1161/CIRCULATIONAHA.122.063399
    Back to article
  25. 25Wan EYF, Fung CSC, Yu EYT, Chin WY, Fong DYT, Chan AKC, et al. Effect of multifactorial treatment targets and relative importance of hemoglobin a1c, blood pressure, and low-density lipoprotein-cholesterol on cardiovascular diseases in Chinese primary care patients with type 2 diabetes mellitus: A population-based retrospective cohort study. J Am Heart Assoc. 2017; 6(8). DOI: 10.1161/JAHA.117.006400
    Back to article
  26. 26Yang X, Liu Q, Fan Y, Ding L, Wang R, Hu G, et al. cardiovascular risk factor status in hospitalized patients with type 2 diabetes in China. Front Endocrinol (Lausanne). 2021; 12:664183. DOI: 10.3389/fendo.2021.664183
    Back to article
  27. 27Mwita, JC, Francis JM, Omech B, Botsile E, Oyewo A, Mokgwathi M, et al. Glycaemic, blood pressure and low-density lipoprotein-cholesterol control among patients with diabetes mellitus in a specialised clinic in Botswana: A cross-sectional study. BMJ Open. 2019; 9(7):e026807. DOI: 10.1136/bmjopen-2018-026807
    Back to article
  28. 28Smith NL, Savage PJ, Heckbert SR, Barzilay JI, Bittner VA, Kuller LH, et al. Glucose, blood pressure, and lipid control in older people with and without diabetes mellitus: The Cardiovascular Health Study. J Am Geriatr Soc. 2002; 50(3):416–23. DOI: 10.1046/j.1532-5415.2002.50103.x
    Back to article
  29. 29Corcillo A, Pivin E, Lalubin F, Pitteloud N, Burnier M, Zanchi A. Glycaemic, blood pressure and lipid goal attainment and chronic kidney disease stage of type 2 diabetic patients treated in primary care practices. Swiss Med Wkly. 2017; 147:w14459. DOI: 10.4414/smw.2017.14459
    Back to article
  30. 30Usman M, Khunti K, Davies MJ, Gillies CL. Association and relative importance of multiple risk factor control on cardiovascular disease, end-stage renal disease and mortality in people with type 2 diabetes: A population-based retrospective cohort study. Prim Care Diabetes. 2021; 15(2):218–226. DOI: 10.1016/j.pcd.2020.08.008
    Back to article
  31. 31Blom DJ, Santos RD, Daclin V, Mercier F, Ruiz AJ, Danchin N, et al. The challenge of multiple cardiovascular risk factor control outside Western Europe: Findings from the International ChoLesterol management Practice Study. Eur J Prev Cardiol. 2020; 27(13):1403–1411. DOI: 10.1177/2047487319871735
    Back to article
  32. 32Ares-Blanco S, Polentinos-Castro E, Rodriguez-Cabrera F, Gullon P, Franco M, Del Cura-Gonzalez I. Inequalities in glycemic and multifactorial cardiovascular control of type 2 diabetes: The Heart Healthy Hoods study. Front Med (Lausanne). 2022; 9:966368. DOI: 10.3389/fmed.2022.966368
    Back to article
  33. 33Wang L, Li X, Wang Z, Bancks MP, Carnethon MR, Greenland P, et al. Trends in prevalence of diabetes and control of risk factors in diabetes among US adults, 1999–2018. JAMA. 2021; 326(8):1–13. DOI: 10.1001/jama.2021.9883
    Back to article
  34. 34Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 139(25):e1082–e1143. DOI: 10.1161/CIR.0000000000000625
    Back to article
  35. 35Jia X, Al Rifai M, Ramsey DJ, Ahmed ST, Akeroyd JM, Nambi V, et al., Association between lipid testing and statin adherence in the Veterans Affairs Health System. Am J Med. 2019; 132(9):e693–e700. DOI: 10.1016/j.amjmed.2019.04.002
    Back to article
  36. 36Rana JS, Virani SS, Moffet HH, Liu JY, Coghlan LA, Vasadia J, et al. Association of low-density lipoprotein testing after an atherosclerotic cardiovascular event with subsequent statin adherence and intensification. Am J Med. 2022; 135(5):603–606. DOI: 10.1016/j.amjmed.2021.11.011
    Back to article
  37. 37Jia X, Ramsey DJ, Rifai MA, Ahmed ST, Akeroyd JM, Dixon DL, et al. Impact of lipid monitoring on treatment intensification of cholesterol lowering therapies (from the Veterans Affairs Healthcare System). Am J Cardiol. 2020; 125(6):874–879. DOI: 10.1016/j.amjcard.2019.12.030
    Back to article
  38. 38Tran C, Vo V, Taylor P, Koehn DA, Virani SS, Dixon DL. Adherence to lipid monitoring and its impact on treat intensification of LDL-C lowering therapies at an urban academic medical center. J Clin Lipidol. 2022; 16(4):491–497. DOI: 10.1016/j.jacl.2022.05.003
    Back to article
  39. 39Kawashiri MA, Sakata K, Hayashi K, Gamou T, Kanaya H, Miwa K, et al. Impact of combined lipid lowering and blood pressure control on coronary plaque: Myocardial Ischemia Treated by Percutaneous Coronary Intervention and Plaque Regression by Lipid Lowering and Blood Pressure Controlling Assessed by Intravascular Ultrasonography (MILLION) study. Heart Vessels. 2017; 32(5):539–548. DOI: 10.1007/s00380-016-0910-2
    Back to article
  40. 40Pagidipati NJ, Nelson, Kaltenbach LA, Leyva M, McGuire DK, Pop-Busui R, et al. Coordinated care to optimize cardiovascular preventive therapies in type 2 diabetes: a randomized clinical trial. JAMA. 2023; 329(15):1261–1270. DOI: 10.1001/jama.2023.2854.
    Back to article
  41. 41Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes [published correction appears in Eur Heart J. 2024 Apr 1;45(13):1145. doi: 10.1093/eurheartj/ehad870.]. Eur Heart J. 2023; 44(38):3720–3826. DOI: 10.1093/eurheartj/ehad191
    Back to article
DOI: https://doi.org/10.5334/gh.1400 | Journal eISSN: 2211-8179
Journal RSS Feed
Language: English
Submitted on: Aug 8, 2024
Accepted on: Jan 31, 2025
Published on: Feb 17, 2025
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Acute coronary syndrome,
Diabetes,
Multifactorial control,
Secondary prevention

© 2025 Jing Yang, Rui Zhang, Bing Han, Hui Li, Jingfeng Wang, Yihui Xiao, Xiaofan Yu, Shaofeng Guan, Cuilian Dai, Hua Yan, Tingbo Jiang, Hanbin Cui, Shuang Yang, Zeqi Zheng, Yugang Dong, Annai Wang, Guohai Su, Yan Wang, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous articleVolume 20 (2025): Issue 1Next article